Events Archives - Page 40 of 128

3 minute read

Decoding The Cannabist Company’s Brand Metamorphosis From Columbia Care, Panel At Benzinga Cannabis Conference

October 10, 5:22 PM

“Well, there was nothing wrong here,” began Jesse Channon, chief commercial officer at The Cannabist Company Holdings Inc (OTC: CCHWF), addressing its

AAPL

2 minute read

Viking Therapeutics To Highlight Data From Phase 1 Clinical Trial Of Dual GLP-1/GIP Receptor Agonist VK2735 In Oral Presentation At ObesityWeek 2023

By Benzinga Newsdesk

October 10, 4:20 PM

Presentation to Highlight VK2735's Preliminary Safety, Tolerability, and PharmacodynamicEffects in Healthy VolunteersSAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a

VKTX

3 minute read

Capricor Therapeutics Announces Late-Breaking Presentations At 28th Annual Congress Of tThe World Muscle Society

By Benzinga Newsdesk

October 10, 9:16 AM

-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002's Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy- -Company's StealthX™ Technology Shows Promise of

CAPR

4 minute read

AbbVie Showcases Breadth And Depth Of Research In Crohn’s Disease And Ulcerative Colitis At UEG Week 2023

By Benzinga Newsdesk

October 10, 8:49 AM

– Late-breaking data from a head-to-head study evaluating SKYRIZI® (risankizumab) versus STELARA® (ustekinumab) in moderate to severe Crohn's disease will be presented– Analyses on

ABBV

3 minute read

Perspective Therapeutics’ VMT-α-NET Protocols Presented At The North American Neuroendocrine Tumor Society 2023 Symposium

By Benzinga Newsdesk

October 10, 8:07 AM

Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), today announced that two upcoming investigator-initiated trials (IIT) were presented at the North American Neuroendocrine Tumor Society

CATX

3 minute read

electroCore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation For Treatment Of Acute Neurological Injury Presented At 2023 World Stroke Congress

By Benzinga Newsdesk

October 10, 8:03 AM

"VANQUISH" Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH) "NOVIS" Clinical Trial (n=150) of nVNS for the acute treatment of

ECOR

1 minute read

Anaptys To Provide Overview Of Rosnilimab, A PD-1 Agonist, At Virtual R&D Event On Wednesday, Oct. 25

By Benzinga Newsdesk

October 9, 8:19 AM

Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology

ANAB

2 minute read

Perspective Therapeutics’ Cesium-131 Featured At The American Society For Radiation Oncology’s

By Benzinga Newsdesk

October 5, 4:12 PM

Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE:CATX), a precision oncology company developing alpha-particle therapies and complementary diagnostic imaging agents and an innovator in seed

CATX

2 minute read

EXCLUSIVE: Curaleaf’s Boris Jordan Puts Premium On Cannabis Quality, Says ‘We Want To Be The Best’

By AJ Fabino

October 5, 12:24 PM

"People are prepared to pay for quality," Curaleaf founder Boris Jordan says at the Benzinga Cannabis Capital Conference.

AAPL

4 minute read

EYLEA HD Injection 8mg Two-Year Results From Pivotal PULSAR Trial In Wet Age-Related Macular Degeneration Presented At EURETINA

By Benzinga Newsdesk

October 5, 9:45 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR trial investigating EYLEA® HD (aflibercept) Injection 8 mg

REGN